Literature DB >> 26202632

Interferon for Chinese patients with chronic hepatitis B e antigen-positive diseases-the controversy arises again?

George K K Lau1,2.   

Abstract

Entities:  

Year:  2014        PMID： 26202632     DOI： 10.1007/s12072-014-9550-8

Source DB:  PubMed          Journal:  Hepatol Int        ISSN： 1936-0533            Impact factor:   6.047


× No keyword cloud information.
  10 in total

1.  Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma.

Authors:  Jessica Liu; Hwai-I Yang; Mei-Hsuan Lee; Sheng-Nan Lu; Chin-Lan Jen; Richard Batrla-Utermann; Li-Yu Wang; San-Lin You; Chuhsing K Hsiao; Pei-Jer Chen; Chien-Jen Chen
Journal:  Gut       Date:  2013-11-13       Impact factor: 23.059

2.  A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone.

Authors:  Henry Lik-Yuen Chan; Nancy Wai-Yee Leung; Alex Yui Hui; Vincent Wai-Sun Wong; Choong-Tsek Liew; Angel Mei-Ling Chim; Francis Ka-Leung Chan; Lawrence Cheung-Tsui Hung; Yuk-Tong Lee; John Siu-Lun Tam; Christopher Wai-Kei Lam; Joseph Jao-Yiu Sung
Journal:  Ann Intern Med       Date:  2005-02-15       Impact factor: 25.391

3.  Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

Authors:  Vincent Wai-Sun Wong; Grace Lai-Hung Wong; Kenneth Kar-Lung Yan; Angel Mei-Ling Chim; Hoi-Yun Chan; Chi-Hang Tse; Paul Cheung-Lung Choi; Anthony Wing-Hung Chan; Joseph Jao-Yiu Sung; Henry Lik-Yuen Chan
Journal:  Hepatology       Date:  2010-06       Impact factor: 17.425

Review 4.  Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection.

Authors:  Yun-Fan Liaw; George K K Lau; Jia-Horng Kao; Edward Gane
Journal:  Dig Dis Sci       Date:  2010-03-18       Impact factor: 3.199

5.  Role of viral factors in the natural course and therapy of chronic hepatitis B.

Authors:  Jia-Horng Kao
Journal:  Hepatol Int       Date:  2007-10-12       Impact factor: 6.047

6.  Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma.

Authors:  Shi-Ming Lin; Ming-Lung Yu; Chuan-Mo Lee; Rong-Nan Chien; I-Shyan Sheen; Chia-Ming Chu; Yun-Fan Liaw
Journal:  J Hepatol       Date:  2006-10-20       Impact factor: 25.083

7.  Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

Authors:  George K K Lau; Teerha Piratvisuth; Kang Xian Luo; Patrick Marcellin; Satawat Thongsawat; Graham Cooksley; Edward Gane; Michael W Fried; Wan Cheng Chow; Seung Woon Paik; Wen Yu Chang; Thomas Berg; Robert Flisiak; Philip McCloud; Nigel Pluck
Journal:  N Engl J Med       Date:  2005-06-30       Impact factor: 91.245

8.  Patients with interferon-induced HBeAg seroconversion have a higher risk of HBV reactivation and HBeAg seroreversion.

Authors:  Chien-Hung Chen; Sheng-Nan Lu; Chuan-Mo Lee; Chao-Hung Hung; Jing-Houng Wang; Tsung-Hui Hu
Journal:  Hepatol Int       Date:  2014-05-31       Impact factor: 6.047

9.  Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update.

Authors:  Yun-Fan Liaw; Jia-Horng Kao; Teerha Piratvisuth; Henry Lik Yuen Chan; Rong-Nan Chien; Chun-Jen Liu; Ed Gane; Stephen Locarnini; Seng-Gee Lim; Kwang-Hyub Han; Deepak Amarapurkar; Graham Cooksley; Wasim Jafri; Rosmawati Mohamed; Jin-Lin Hou; Wan-Long Chuang; Laurentius A Lesmana; Jose D Sollano; Dong-Jin Suh; Masao Omata
Journal:  Hepatol Int       Date:  2012-05-17       Impact factor: 6.047

10.  Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion.

Authors:  Hung-Chih Yang; Chi-Ling Chen; Yueh-Chi Shen; Cheng-Yuan Peng; Chun-Jen Liu; Tai-Chung Tseng; Tung-Hung Su; Wan-Long Chuang; Ming-Lung Yu; Chia-Yen Dai; Chen-Hua Liu; Pei-Jer Chen; Ding-Shinn Chen; Jia-Horng Kao
Journal:  Hepatology       Date:  2013-02-07       Impact factor: 17.425
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.